purinergic受体 (P2X7R):一个有前途的抗帕金森病药物点
Saivarshini Magham1, M Lalith Kumar1, Praveen Thaggikuppe Krishnamurthy1
1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty-643001, The Nilgiris, Tamil Nadu, India.
Advanced pharmaceutical bulletin
|April 7, 2025
概括
用对抗剂向Purinergic 2X7受体 (P2X7R) 显示出对帕金森病 (PD) 治疗有希望. 这些抗体可能通过减少炎症来提供神经保护,这是PD病理学的关键因素.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 帕金森病 (PD) 是一种主要的神经退行性疾病,与多巴胺耗尽和神经炎症有关.
- 纯能2X7受体 (P2X7Rs) 起到关键的炎症调节作用,特别是在中枢神经系统和外围神经系统内的质细胞中.
- 在质细胞中P2X7Rs的过度表达对PD中观察到的神经炎症有显著的贡献.
研究的目的:
- 审查P2X7受体的结构,信号和分子机制.
- 探索P2X7受体对抗剂在帕金森病中的神经保护作用.
- 要总结PD治疗P2X7受体对抗剂研究当前的发展情况.
主要方法:
- 系统分析和审查现有研究数据和报告.
- 文学搜索集中在1996年至今的出版物上.
- 对调查P2X7R和PD病理学之间的联系的研究进行分析.
主要成果:
- 在P2X7受体活性和帕金森病的病理学之间存在强烈的相关性.
- P2X7受体对抗剂在治疗PD方面具有显著的治疗潜力.
- 有证据表明,P2X7R对抗剂可以防止像IL-1这样的炎症媒介的释放,提供神经保护.
结论:
- P2X7受体是帕金森病的有效治疗点.
- 药物设计的进步导致了有前途的P2X7受体对抗剂的开发,包括阿达曼酸和小分子化合物.
- 需要进一步的研究,以充分阐明PD中P2X7受体对抗剂的分子机制和治疗疗效.
更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.3K
09:49Brain Membrane Fractionation: An Ex Vivo Approach to Assess Subsynaptic Protein Localization
Published on: May 12, 2017
10.3K
相关概念视频
01:24Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161
01:15Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:15G Protein-coupled Receptors
10.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.9K
01:26Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K